Position of the Transparency Council – Livmarli (maralixibat chloride)

At its meeting on 12 May 2025, the Transparency Council adopted position No. 55/2025 on the appraisal of drug Livmarli (maralixibat chloride) under the drug program “Treatment of patients with Alagille syndrome (ICD-10 Q44.7)”